# GILEAD SCIENCES, INC. (GILD) · Edgar & Edgarette company card

> Gilead Sciences (GILD) grew revenue 2.4% in FY2025 to $29.4 billion, operating margin 34.0% against a -15.8% median for biological products, (no diagnostic substances), equity 38.5% of assets, and dividend per share up 11 years running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 882095 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/GILD) · [JSON](https://www.pops4.com/boards/company/GILD.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $29.4B |
| Revenue growth, 1 year | 2.4% |
| Revenue growth per year | 1.9% |
| Operating margin | 34.0% (prior year 5.8%) |
| Net margin | 28.9% |
| Operating cash flow | $10.0B |
| Capital spending | $563M |
| Free cash flow | $9.5B |
| Cash | $7.6B |
| Long-term debt | $24.9B |
| Total assets | $59.0B |
| Total equity | $22.7B |
| Equity ÷ assets | 38.5% |
| Return on equity | 37.5% |
| Dividend per share | $3.16 |
| Dividend years rising | 11 |

## Readings, computed from those figures

- Altman Z: 3.28 (safe zone)
- Piotroski F: 8 of 9 (strong)
- Beneish M: -2.45 (below the −1.78 line)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Cash cow now · steady, with strong cash arriving today

## Edgarette's reading

Exposure: revenue $29.4B (FY2025), total debt $24.9B. Experience: revenue up 2.4% on the year, up 1.9% a year over 4 years; operating margin 34.0%, up from 5.8%. Soundness: equity 38.5% of assets, return on equity 37.5%, payout 47.0% of profit, dividend per share up 11 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $27.2B and $31.3B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $25.6B to $33.1B. A statistical range, not company guidance. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin 34.0% against a -15.8% median; growth 2.4% against 21.4%.

Range logged 2026-09-26, receipt 96162e2b322f83b1, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2025-11-19 ([filing](https://www.sec.gov/Archives/edgar/data/882095/000110465925113968/0001104659-25-113968-index.htm))

## Recent filings

- 10-Q · filed 2026-10-30 · [filing](https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/882095/000088209526000037/0000882095-26-000037-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/0000882095-26-000031-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/0000882095-26-000028-index.htm)
- 8-K · filed 2026-05-20 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/882095/000110465926064518/0001104659-26-064518-index.htm)
- 10-Q · filed 2026-05-07 · [filing](https://www.sec.gov/Archives/edgar/data/882095/000088209526000024/0000882095-26-000024-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000882095.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=882095

## Cite

POPS4, Edgar & Edgarette: GILEAD SCIENCES, INC. (GILD) company card, from the company's own SEC filings, accessed 2026-11-10, https://www.pops4.com/boards/company/GILD. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.